Zobrazeno 1 - 9
of 9
pro vyhledávání: '"AIDA Regimen"'
Autor:
Lourdes Escoda, Manuel Barrios, Isabel Krsnik, Olga Salamero, Fernando Ramos, Susana Vives, Jalanta Oleksiuk, Manuel Pérez-Encinas, Félix Manso, David Martínez-Cuadrón, José González-Campos, Marta Sobas, Cristina Gil, Pau Montesinos, Andrés Novo, Celina Benavente, Josefina Serrano, Javier de la Serna, Salut Brunet, Miguel A. Sanz, Jordi Esteve, Mari-Luz Amigo, Pethema, Raimundo García-Boyero, J. Arias, Palg Groups
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
PETHEMA And PALG Groups.
Acute promyelocytic leukemia is infrequent among patients aged ≥75 years old, a population that is rarely eligible for clinical protocols. This study aims to analyze the treatment strategies and clinical outcomes of ve
Acute promyelocytic leukemia is infrequent among patients aged ≥75 years old, a population that is rarely eligible for clinical protocols. This study aims to analyze the treatment strategies and clinical outcomes of ve
Autor:
Andreza Lamonica, Ana Carolina Mourão Toreli, Paulo Vittor Oliveira Peres, Eduardo Magalhães Rego, Katia B Pagnano, Mariana Dos Santos Pastori, Camilla Maria de Alencar Saraiva, Bruno Kosa Lino Duarte
Publikováno v:
Blood. 132:5874-5874
INTRODUCTION:Acute promyelocytic leukemia (APL) is the most curable acute leukemia in adults. Advancements in therapeutics such as the use of tretinoin (ATRA) and arsenic trioxide (ATO) have led to an overall survival of over 90% in 5 years. Early mo
Publikováno v:
Medical Oncology. 28:279-281
Differentiation syndrome (DS) is a life-threatening complication observed in patients with acute promyelocytic leukemia (APL) receiving induction therapy with all-trans-retinoic acid (ATRA). A bimodal incidence of DS has been observed, with a majorit
Autor:
Massimo Breccia, Mariella D'Andrea, Giuseppe Gentile, F Lo Coco, Antonio Spadea, Roberto Latagliata, P. Martino, Giuliana Alimena, Corrado Girmenia, Franco Mandelli, Alessandra Micozzi
Infections represent a frequent complication of chemotherapy used for acute myeloid leukaemia (AML) and are associated with important toxicity frequently leading to treatment discontinuation. Acute promyelocytic leukaemia (APL) is a unique AML subset
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::431550ea1a5a180d5e4be83b6b98dcfb
http://hdl.handle.net/2108/162093
http://hdl.handle.net/2108/162093
Autor:
Felicetto Ferrara, Hartmut Link, Francesco Lo-Coco, Enrica Morra, Mohammed Wattad, Christian Brandts, Uwe Platzbecker, Sergio Amadori, Eros Di Bona, Norbert Schmitz, Arnold Ganser, Marco Vignetti, Richard F. Schlenk, Fabio Ciceri, Sonia Maria Orlando, Mariadomenica Divona, Giuseppe Avvisati, Bernd Hertenstein, Elisa Cerqui, M. Sauer, Giuseppe Fioritoni, Giorgina Specchia, Michael Lübbert, Christian Thiede, Mario Luppi, Hartmut Döhner, Alessandro Rambaldi, Marie von Lilienfeld-Toal, Franco Mandelli, Paola Fazi, Gerhard Ehninger, Maria Grazia Kropp, Giorgio La Nasa, M Hänel, Massimo Breccia, Helmut R. Salih, Alessandro Levis, Simona Sica, Walter Fiedler
Publikováno v:
Blood. 120:6-6
Abstract 6 Background Simultaneous ATRA and chemotherapy (CHT) is the current gold standard for newly diagnosed APL resulting in ∼80% cure rates, while arsenic trioxide (ATO) is the treatment of choice for relapsed patients. ATO in variable combina
Autor:
Deok-Hwan Yang, Yeo-Kyeoung Kim, Hee-Je Kim, Il-Kwon Lee, Hyeoung-Joon Kim, Hee Nam Kim, Woo-Sung Min, Deog-Yeon Jo, Moo-Rim Park, Jae-Sook Ahn, Je-Jung Lee, Jong Ho Won
Publikováno v:
Blood. 112:4846-4846
Background: Although the most powerful prognostic factor of acute myeloid leukemia (AML) patients is the karyotype of the leukemic blast, data have not been obtained almost entirely in patients with heterogeneous cytogenetics. Further, some patients
Autor:
Manuel Perez-Encina, Angel Leon, Juan Bergua, Chelo Rayon, Javier Bueno, Antonia Rodriguez, José D. González, Guillermo Martin, Javier de la Serna, Guillermo Deben, Silvia Negri, Elena Amutio, Marcos González, Miguel A. Sanz, Ricardo Parody, Francisco Javier Capote, Jaoquin Diaz-Mediavilla, Edo Vellenga, Mar Tormo, Andrés Novo, Jordi Esteve, Concha Rivas
Publikováno v:
Blood. 104:887-887
The simultaneous combination of ATRA and anthracycline-based chemotherapy has resulted in a major improvement in remission induction rate and long term survival in patients with APL. This benefit is mainly due to an increased antileukemic efficacy, l
Autor:
Chelo Rayon, Jordi Esteve, Javier de la Serna, Aleksandra Holowiecka, Angel Leon, Pau Montesinos, Juan Bergua, Concha Rivas, José González, Gustavo Milone, Edo Vellenga, Miguel A. Sanz
Publikováno v:
Publons
Background: Pseudotumor cerebri associated with all-trans-retinoic acid (ATRA) treatment in acute promyelocytic leukemia (APL) have been frequently described in pediatric patients. However, the incidence, outcome and risk factors of pseudotumor cereb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::923fdad0a9d3dc2b179acab226653f33
https://publons.com/publon/25161998/
https://publons.com/publon/25161998/
Autor:
Javier de la Serna, José D. González, Aleksandra Holowiecka, Gustavo Milone, Marcos González, Pau Montesinos, Joaquín Díaz Mediavilla, Salut Brunet, Angel Leon, Chelo Rayon, Javier Bueno, José M. Ribera, Juan Bergua, Elena de Lisa, Concha Rivas, José González, Miguel A. Sanz, Isabel Krsnik
Publikováno v:
Publons
Background: A previous report of the PETHEMA Group (Sanz et al, Blood 2004) showed that a risk-adapted strategy combining ATRA and anthracycline monochemotherapy for induction and consolidation (LPA99 trial), followed by ATRA and low dose methotrexat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c812220c7292c2873a908e7953ebd5e
https://publons.com/publon/25161996/
https://publons.com/publon/25161996/